A database of FDA approved therapeutic peptides and proteins
| This page displays user query in tabular form. |
1814 details |
| Primary information | |
|---|---|
| ThPP ID | Th1205 |
| Therapeutic Peptide/Protein Name | Obiltoxaximab |
| Sequence | NA view full sequnce in fasta |
| Functional Classification | IIIa |
| Molecular Weight | 148000 |
| Chemical Formula | NA |
| Isoelectric Point | NA |
| Hydrophobicity | NA |
| Melting Point (℃) | NA |
| Half Life | NA |
| Description | Obiltoxaximab, an affinity-enhanced monoclonal antibody (Mab), is used for prevention and treatment of infection and death caused by anthrax toxin. Obiltoxaximab is a chimeric IgG1 kappa monoclonal antibody (mAb) that binds the PA component of B. anthracis toxin. It has an approximate molecular weight of 148 kDa. |
| Indication/Disease | Investigated for use/treatment in anthrax exposure, bacterial infection, crohn's disease, and graft versus host disease. |
| Pharmacodynamics | NA |
| Mechanism of Action | ETI-204 is an affinity-enhanced, de-immunized antibody, which means that its ability to bind to its target pathogen has been strengthened and that elements that might cause an immune response have been removed. ETI-204 targets and binds to Protective Antigen, which prevents the anthrax toxins from binding to and entering the cells in the body, thereby preventing death. |
| Toxicity | NA |
| Metabolism | NA |
| Absorption | Mean Cmax and AUCinf were 400 ± 91.2 mcg/mL and 5170 ± 1360 mcg•day/mL, respectively. |
| Volume of Distribution | NA |
| Clearance | NA |
| Categories | NA |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | NA |
| Target | NA |
| Information of corresponding available drug in the market | |
| Brand Name | Anthim |
| Company | Elusys Therapeutics, Inc. |
| Brand Discription | Obiltoxaximab is a chimeric IgG1 kappa monoclonal antibody (mAb) that binds the PA component of B. anthracis toxin. |
| Prescribed for | ANTHIM is indicated in adult and pediatric patients for the treatment of inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs.; Also is indicated for prophylaxis of inhalational anthrax due to B. anthracis when alternative therapies are not available or not appropriate. |
| Chemical Name | NA |
| Formulation | Solution |
| Physcial Appearnce | Liquid |
| Route of Administration | Intravenous infusion |
| Recommended Dosage | The recommended dosage of ANTHIM in adult patients is a single dose of 16 mg/kg administered intravenously over 90 minutes (1 hour and 30 minutes); For adult patients weighing less than 40 kg. |
| Contraindication | NA |
| Side Effects | Hypersensitivity and Anaphylaxis |
| Useful Link | http://www.rxlist.com/anthim-drug/side-effects-interactions.htm |
| PubMed ID | 27925405, 27568215, 27431222, 27431219, 27313431, 27085536, 26651519, 25484055, 25484055 |
| 3-D Structure | N.A. |